Phase 2 Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with either Inflammatory Bowel Disease (IBD) or Rheumatic Disease (RD)
- Your disease is currently active — for IBD, this means your bowel disease is at least mildly active (confirmed by a doctor's assessment or a stool test result above a certain level); for Rheumatic Disease, this means at least one joint in your hand is currently inflamed, as confirmed by a specialist
- You are 18 years old or older and are able to make your own decisions
- You are willing and able to sign a written consent form
- If you have IBD, you must already have a colonoscopy (camera test of the bowel) booked for medical reasons
- If you are a woman who could become pregnant, you must have a negative pregnancy test before joining, and be willing to use effective contraception during the study and for 3 months afterwards
Who may not be able to join:
- People whose physical or mental health conditions prevent them from fully understanding and agreeing to take part
- Women who are currently pregnant or breastfeeding
- Patients with Rheumatic Disease who have a darker skin tone above a certain level on a medical skin colour scale (called the Fitzpatrick scale, type 3 or above), due to limitations of the measurement equipment used in the study (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wouter B. Nagengast, MD, PhD, PharmD, University Medical Center Groningen
Phone: +31503612620
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety: number of participants with symptoms or changes in vital signs (blood pressure, heart rate and temperature) that are related to administration of adalimumab-800CW; Safety: number of participants with (serious) adverse events that are related to the administration of adalimumab-800CW; Discrimination of inflamed and normal tissue based on in vivo fluorescence measurements from adalimumab-800CW gained during fluorescence imaging of the hand of rheumatoid arthritis patients; Discrimination of inflamed and normal tissue based on in vivo and ex vivo fluorescence measurements from adalimumab-...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.